Preview

Advances in Molecular Oncology

Advanced search

Pancreatic neuroendocrine tumors: new aspects of morphological classification (World Health Organization, 2017)

https://doi.org/10.17650/2313-805X-2017-4-3-104-108

Abstract

The fourth edition of the World Health Organization (WHO) classification of endocrine tumors published in 2017 contains substantial new findings in the topics of pancreatic neuroendocrine neoplasms (PanNENs). In this edition, major modifications are mainly based on new molecular knowledge as well as the clinical behaviour of these tumors accommodated since the previous 2010 classification of degestive tumors was published. According to the new classification scheme PanNENs include malignant well-differentiated neuroendocrine neoplasms (NENs), which are called pancreatic neuroendocrine tumors (PanNETs), and poorly differentiated NENs, which are called pancreatic neuroendocrine carcinomas (PanNECs). PanNENs futher divided into three Grade (G) on the base of cell proliferation: G1 (<2 mitoses on 10 HPF (high-power field) and Ki-67 Index <3 %), G2 (2–20 mitoses on 10 HPF or Ki-67 Index 3–20 %), G3 (>20 mitoses on 10 HPF or Ki-67 Index >20 %). The new category NET G3 was first introduced in this edition of the WHO classification. PanNECs is classified as G3 neoplasms (>20 mitoses on 10 HPF or Ki-67 Index >20 %) and additionally divided into small cell NEC and large cell NEC. In this review we focus on some of the new features of PanNETs and recommended changes of their terminology and classification.

About the Author

V. V. Delektorskaya
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.


References

1. Lloyd R.V., Osamura R.Y., Kloppel G., Rosai J. WHO classification of tumours of endocrine organs. 4th edn. Lyon: IARC Press, 2017.

2. Bosman F. WHO classification of tumours of the digestive system. Lyon: IARC Press, 2010.

3. Ohmoto A., Rokutan H., Yachida S. Pancreatic neuroendocrine neoplasms: basic biology, current treatment strategies and prospects for the future. Int J Mol Sci 2017;18(1):143.

4. Reid M.D., Balci S., Saka B., Adsay N.V. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol 2014;25(1): 65–79.

5. Rindi G., Falconi M., Klersy C. et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. Natl Cancer Inst 2012;16(104): 764–77.

6. Rindi G., Kloppel G., Alhman H. et al. TNM staging of foregut (neuro)endocrine tumours: a consensus proposal including a grading system. Virchows Arch 2006;449(4):395–401.

7. Bergsland E.K., Woltering E.A., Rindi G. et al. Neuroendocrine tumors of the pancreas. In: American Joint Committee on Cancer (AJCC). 8th edn. AJCC Cancer Staging Manual. Chicago: Springer, 2017. Pp. 407–419.


Review

For citations:


Delektorskaya V.V. Pancreatic neuroendocrine tumors: new aspects of morphological classification (World Health Organization, 2017). Advances in Molecular Oncology. 2017;4(3):104-108. (In Russ.) https://doi.org/10.17650/2313-805X-2017-4-3-104-108

Views: 903


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2313-805X (Print)
ISSN 2413-3787 (Online)